Ovarian Neoplasms: all 2,757 studies
Page 21 of 28. Open to participants first (735), then studies with results posted, then the rest; newest registration first within each.
- Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian CancerCompletedNCT02520115Phase 1
- C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer PopulationCompletedNCT02503436
- Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian CancerActive, not recruitingNCT02494791Not applicable
- The Canadian/US Integrative Oncology StudyCompletedNCT02494037
- Interest of the Manual Exploration as a Supplement to the Coelioscopy in the Evaluation of the Resectability of Peritoneal CarcinosisCompletedNCT02493972Not applicable
- Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer PatientsCompletedNCT02490488Phase 2/3
- A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube CancerActive, not recruitingNCT02489006Phase 2
- HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian CarcinomaWithdrawnNCT02487849Phase 2
- Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian CarcinomaActive, not recruitingNCT02487693Phase 2
- Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian CancerCompletedNCT02483104Phase 1
- Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid TumoursCompletedNCT02482311Phase 1
- TIL Therapy for Metastatic Ovarian CancerCompletedNCT02482090Phase 1
- Venous Thromboembolic Complications in Ovarian CancerStatus unknownNCT02480790
- Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian CancerCompletedNCT02480374Phase 1
- DNA Single Nucleotide Polymorphisms as Predictors of ToxicityStatus unknownNCT02478476
- Platine, Avastin and OLAparib in 1st LineCompletedNCT02477644Phase 3
- Open-label Phase 1b Study of ARQ 092 in Combination With AnastrozoleTerminatedNCT02476955Phase 1
- A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal CarcinomatosisCompletedNCT02475772Phase 1
- Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or RecurrentWithdrawnNCT02470559Phase 1
- Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer PatientsCompletedNCT02470299Not applicable
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
- Biobehavioral Intervention in Gynecologic Oncology PatientsCompletedNCT02454036Phase 2
- Autologous OC-L Vaccine and Ovarian CancerTerminatedNCT02452775Phase 1
- Guided Imagery in the Perioperative Period in Gynecologic Oncology PatientsCompletedNCT02444195Not applicable
- Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by CuldocentesisTerminatedNCT02441140Not applicable
- Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian CarcinomaStatus unknownNCT02437812Phase 2
- Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC VaccinesWithdrawnNCT02432378Phase 1/2
- Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their CaregiversTerminatedNCT02412124Not applicable
- Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian CancerStatus unknownNCT02408536
- Phase I Trial of VS-6766 Alone and in Combination With EverolimusCompletedNCT02407509Phase 1
- Taking Care of Her Program in Patients With Stage III or IV Ovarian Cancer and Spouse CaregiversCompletedNCT02401321Not applicable
- Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian CancerCompletedNCT02399592Phase 2
- Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPCCompletedNCT02394015
- BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and OlderCompletedNCT02393898
- Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes MutationsWithdrawnNCT02392676Phase 3
- Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian CancerCompletedNCT02383251Phase 2
- To Evaluate Plasmajet in Achieving Complete Cytoreduction of Advanced EOC- Initial Feasibility StudyCompletedNCT02376231Not applicable
- Salpingectomy at Cesarean Delivery for Ovarian Cancer Reduction (SCORE)CompletedNCT02374827Not applicable
- Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian CancerCompletedNCT02354131Phase 1/2
- Hula, a Physical Activity Intervention for Female-Cancer SurvivorsCompletedNCT02351479Not applicable
- A Trial of Vigil for Participants With Ovarian CancerActive, not recruitingNCT02346747Phase 2
- Detection of Chlamydia DNA by Polymerase Chain Reaction in Primary Tubal and Ovarian Cancers Tissues : a Pilot StudyCompletedNCT02343510
- Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.TerminatedNCT02341118
- A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on OlaparibCompletedNCT02340611Phase 2
- MR-PET for Staging and Assessment of Operability in Ovarian Cancer - a Feasibility StudyCompletedNCT02334371Not applicable
- Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal CarcinomaStatus unknownNCT02328716Phase 3
- Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: a Feasibility StudyCompletedNCT02324595Phase 2
- Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in RemissionCompletedNCT02324439Phase 1
- Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs.CompletedNCT02323568Not applicable
- DOD Long-Term Survivors of Ovarian CancerStatus unknownNCT02321735Not applicable
- Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation CarriersActive, not recruitingNCT02321228Not applicable
- Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02316834Early Phase 1
- Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian CancerCompletedNCT02312661Phase 1
- Feasibility Study for Robotic Endomicroscopy to Better Define Resection Strategies (PERSEE)CompletedNCT02312167Not applicable
- Yoga Practice for Breast or Ovarian Cancer PatientsCompletedNCT02305498Not applicable
- Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian CancerCompletedNCT02303912Phase 1
- Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced CancerActive, not recruitingNCT02298959Phase 1
- Individualised Versus Conventional Medical Follow-up for Women After Primary Treatment for Ovarian Cancer.CompletedNCT02298855Not applicable
- Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian CarcinomaCompletedNCT02297958
- Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot InterventionCompletedNCT02287519Not applicable
- Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast CancerCompletedNCT02270372Phase 1
- Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer AgentsActive, not recruitingNCT02264678Phase 1
- Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid TumorsCompletedNCT02262455Phase 1
- OSCA - Olaparib Standard of CAre StudyCompletedNCT02262273
- Impact of Gated PET/CT in the Diagnosis of Advanced Ovarian CancerCompletedNCT02258165
- Short-course HIPEC in Advanced Epithelial Ovarian CancerCompletedNCT02249013Phase 2
- Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)Status unknownNCT02244502Phase 1/2
- Magnetic Resonance Imaging for Lymph Node Staging in Ovarian CancerWithdrawnNCT02243059Phase 4
- Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian CancerCompletedNCT02237690Phase 1
- Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian TumorsCompletedNCT02227654Not applicable
- Cancer Prevention in Women With a BRCA MutationStatus unknownNCT02225015Phase 1
- Prevalence of BRCA in Patients With Ovarian CancerCompletedNCT02222883
- Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Procedures.CompletedNCT02221076Not applicable
- Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal MassesTerminatedNCT02218502Not applicable
- mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianActive, not recruitingNCT02208375Phase 1
- Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian CancerCompletedNCT02195973Phase 1
- Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family MembersActive, not recruitingNCT02194387Not applicable
- Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial CancerStatus unknownNCT02188550Phase 2
- Safety and Effectivity Immunotherapy to Treat Ovarian Cancer With Cancer Stem Cells VaccineCompletedNCT02178670Phase 1/2
- Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)CompletedNCT02163720
- Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary CancerStatus unknownNCT02159820Phase 2/3
- Why do Oral Contraceptives Prevent Ovarian Cancer?CompletedNCT02155777Early Phase 1
- An Observational Study of Avastin (Bevacizumab) in Patients With Ovarian CancerCompletedNCT02151370
- A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic CancerCompletedNCT02146313Phase 1
- Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And GenomicsCompletedNCT02144311Not applicable
- The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical TrialCompletedNCT02135523Not applicable
- Decision Support Following Genetic Testing for Breast-Ovarian Cancer SusceptibilityCompletedNCT02133703Not applicable
- Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian CancerStatus unknownNCT02132988Phase 2
- Neoadjuvant Chemotherapy in Epithelial Ovarian CancerStatus unknownNCT02125513Phase 2
- HOT: HIPEC in Ovarian Cancer as Initial TreatmentActive, not recruitingNCT02124421Phase 2
- OVArian Cancer Non-Interventional Study - OVATARCompletedNCT02122588
- Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerCompletedNCT02118285Phase 1
- Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian CancerWithdrawnNCT02117817Phase 1
- Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT02111941Early Phase 1
- Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal MassCompletedNCT02109367
- Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian CarcinomaCompletedNCT02107950Phase 2
- Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian CarcinomaCompletedNCT02107937Phase 2
- Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian CarcinomaTerminatedNCT02107378Phase 2
- Women's Activity and Lifestyle Study in ConnecticutCompletedNCT02107066Phase 3
- Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.TerminatedNCT02101684Phase 2